Seeking Alpha
 

Supernus Pharmaceuticals, Inc. (SUPN)

- NASDAQ
  • Fri, Jun. 19, 8:14 AM
    • VistaGen Therapeutics (OTCQB:VSTA) initiated with Buy rating and $50 (257% upside) price target by Chardan Capital Markets.
    • Axovant Sciences (NYSE:AXON) initiated with Sell rating and $10 (48% downside risk) price target by Chardan Capital Markets.
    • Omnicell (NASDAQ:OMCL) initiated with Outperform rating and $44 (14% upside) price target by Oppenheimer.
    • Juno Therapeutics (NASDAQ:JUNO) initiated with Buy rating and $78 (50% upside) price target by Maxim Group.
    • Molina Healthcare (NYSE:MOH) initiated with Buy rating and $80 (18% upside) price target by UBS.
    • Pfizer (NYSE:PFE) initiated with Overweight rating and $45 (32% upside) price target by Jefferies.
    • Supernus Pharmaceuticals (NASDAQ:SUPN) upgraded to Buy from Hold with an $18 (6% upside) price target by Jefferies.
    • Lumenis (NASDAQ:LMNS) downgraded to Market Perform from Outperform by Wells Fargo. Not surprising since XIO Group will acquire at $14 per share.
    | 3 Comments
  • Tue, Jun. 16, 9:24 AM
    | 5 Comments
  • Fri, Jun. 12, 12:45 PM
    | Comment!
  • Fri, Jun. 12, 12:17 PM
    • AMAG Pharmaceuticals (AMAG -1.5%) initiated with Hold rating and $75 (10% upside) price target by Deutsche Bank.
    • Supernus Pharmaceuticals (SUPN +9.5%) initiated with Buy rating and $30 (70% upside) price target by SunTrust Robinson Humphrey.
    • Plasmatech Biopharmaceuticals (PTBI -2.7%) initiated with Buy rating and $16 (118% upside) price target by Roth Capital.
    • Horizon Pharma (HZNP -0.4%) initiated with Overweight rating and $38 (19% upside) price target by Morgan Stanley.
    • Depomed (DEPO -2.1%) initiated with Equal Weight rating and $23 (10% upside) price target by Morgan Stanley.
    • Community Health Systems (CYH +0.5%) initiated with Outperform rating and $65 (19% upside) price target by Wedbush.
    • HCA Holdings (HCA -0.1%) initiated with Outperform rating and $93 (11% upside) price target by Wedbush.
    • LifePoint Health (LPNT -0.2%) initiated with Neutral rating and $80 (5% upside) price target by Wedbush.
    • HealthSouth (HLS) initiated with Neutral rating and $46 (3% downside risk) price target by Wedbush.
    • Adeptus Health (ADPT -0.4%) initiated with Overweight rating and $106 (26% upside) price target by KeyBanc.
    • Universal Health Services (UHS -0.1%) initiated with Neutral rating and $141 (7% upside) price target by Janney Capital.
    • Owens & Minor (OMI -0.2%) initiated with Sector Perform rating and $35 (3% upside) price target by RBC Capital.
    • Henry Schein (HSIC -0.6%) initiated with Outperform rating and $165 (16% upside) price target by RBC Capital.
    | 5 Comments
  • Fri, Jun. 5, 5:37 PM
    | Comment!
  • Thu, Jun. 4, 6:19 PM
    • Manhattan Associates (NASDAQ:MANH) will replace Life Time Fitness (about to be taken private) in the S&P MidCap 400 following the June 10 close. Supernus Pharma (NASDAQ:SUPN) will take Manhattan's place in the S&P SmallCap 600.
    • Manhattan has risen to $56.49 in AH trading, and Supernus to $15.27 (a new 52-week high).
    | 2 Comments
  • Thu, Jun. 4, 5:35 PM
    | 17 Comments
  • Tue, May 5, 4:54 PM
    • Supernus Pharmaceuticals (NASDAQ:SUPN): Q1 EPS of $0.02 beats by $0.03.
    • Revenue of $28.1M (+208.8% Y/Y) misses by $1.21M.
    • Press Release
    | Comment!
  • Tue, Mar. 10, 5:06 PM
    • Supernus Pharmaceuticals (NASDAQ:SUPN): Q4 EPS of $0.08 beats by $0.21.
    • Revenue of $30.8M (+198.2% Y/Y) beats by $6.44M.
    • Shares -2% AH.
    • Press Release
    | Comment!
  • Mon, Mar. 9, 5:35 PM
  • Nov. 12, 2014, 12:59 PM
    • Supernus Pharmaceuticals (SUPN +7.3%) Q3 results: Revenues: $52.5M (+999%); R&D Expense: $4.7M (+23.7%); SG&A: $17.3M (+18.5%); Operating Income: $29.2M (+269.8%); Net Income: $27.9M (+215.8%); EPS: $0.39 (+150.0%); Quick Assets: $72.6M (-11.7%).
    • 2014 Guidance: Revenue: $115M - 118M from ~$105M; cash burn: ~$5M from $5M - 10M; quick assets at year end: ~$85M from $75M - 85M.
    • 2015 Guidance: Company anticipates achieving cash flow break even and being profitable.
    | Comment!
  • Nov. 12, 2014, 9:18 AM
    | Comment!
  • Nov. 11, 2014, 5:38 PM
    | 4 Comments
  • Nov. 11, 2014, 4:32 PM
    • Supernus Pharmaceuticals (NASDAQ:SUPN): Q3 EPS of $0.39 beats by $0.03.
    • Revenue of $52.5M beats by $9.42M.
    • Press Release
    | Comment!
  • Nov. 10, 2014, 5:35 PM
  • Sep. 24, 2014, 4:56 PM
    • Supernus Pharmaceuticals (SUPN +1.8%) says that it should be cash flow breakeven by the end of 2014 with a cash balance of $75M - 85M.
    • It expects to be profitable this year and beyond and does not need to raise new capital to reach profitability.
    • Full year revenue will be ~$105M.
    | Comment!
Visit Seeking Alpha's
SUPN vs. ETF Alternatives
Company Description
Supernus Pharmaceuticals Incis a specialty pharmaceutical company. The Company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
Sector: Healthcare
Industry: Drugs - Generic
Country: United States